Treatment of keratoacanthoma centrifugum marginatum with topical tretinoin

Binitha, MP; Riyaz, Najeeba; Pabin, Rahima P

doi:10.4103/2229-5178.86009

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intralesional corticosteroids were also considered as a therapeutic option for KA, although the majority of results have shown that they were not as effective as other currently available alternatives (Belisario, 1965;Binitha, Najeeba, & Pabin, 2011;Burket & Caplan, 1964;Cipollaro, 1983;Consigli et al, 2000;Epstein Jr. & Epstein, 1978;Epstein, 2010;Ereaux & Schopflocher, 1965;Friedman, Morales, & Burnham, 1965;Jolly Jr. & Carpenter Jr., 1966;Kingman & Callen, 1984;McNairy, 1964;Reager, 1968;Reid & Cheesbrough, 1978;Sanders, Busam, Halpern, & Nehal, 2002). Unlike their classic mechanism of action, which utilizes their immunosuppressive effects, when treating KA, corticosteroids were suggested to exert their effects via different pathways.…”

Section: Corticosteroidsmentioning

confidence: 99%

Intralesional therapy for the treatment of keratoacanthoma

Kiss

Avci

Bánvölgyi

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Keratoacanthoma (KA) is a common epidermal tumor that originates from the hair follicle of the skin. It is generally considered as a benign neoplasm, but in rare cases, it can also transform into squamous cell carcinoma. Although surgical excision with a safety margin is considered to be the gold standard treatment for most subtypes of KA, several other treatment options are also available. Intralesional therapy is one of these options, which could be cosmetically and functionally a better alternative to surgical removal, while it provides similar outcomes. It is more effective than topical treatments, yet fewer side effects may be seen than in systemic treatments. Based on the literature, the most commonly used intralesional agent is methotrexate, followed by 5‐fluorouracil and interferon alpha. Regardless of the advantages, which make intralesional therapy a desirable treatment alternative, guidelines for the intralesional treatment of KA are not yet established. A histopathological confirmation before the start of treatment is still recommended to prevent any possible misdiagnosis of KA for SCC. In our present study, we set out to review the current state of the art of the intralesional treatment of KA.

show abstract